Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 11/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | HINT1 | P49773 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | FUT6 | P51993 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6831440 | 0.87 | TYMP (0.48) | TAAR1TYMPHPGDKRASTAS1R3 | |
| SCHEMBL7073590 | 0.87 | POLB (0.39) | TAAR1TYMPHPGDKRASTAS1R3 | |
| SCHEMBL6234136 | 0.87 | TAAR1 (0.39) | TAAR1TYMPHPGDKRASTAS1R3 | |
| SCHEMBL7074770 | 0.82 | P2RX3 (0.41) | TYMP | |
| SCHEMBL17599828 | 0.81 | TYMP (0.49) | TAAR1TYMPHPGDTAS1R3TAS1R1 | |
| SCHEMBL6836526 | 0.80 | TYMP (0.36) | TAAR1TYMPHPGDKRASTAS1R3 | |
| SCHEMBL6835151 | 0.80 | TYMP (0.36) | TAAR1TYMPHPGDKRASTAS1R3 | |
| SCHEMBL9320640 | 0.80 | TAAR1 (0.44) | TAAR1TYMPHPGDKRASTAS1R3 | |
| SCHEMBL16401878 | 0.79 | TYMP (0.49) | TAAR1TYMPHPGDKRASHINT1 | |
| SCHEMBL7074034 | 0.78 | ST6GAL1 (0.38) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948514-B1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | GRIFFEY RICHARD H (US) | 2003-01-16 | — | — | US | disclosed |
| US-6458941-B1 | RECOVERED FROM WASTE PRODUCTS OF OLIGONUCLEOTIDE BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6441150-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | NUDT1, MTAP, PHOSPHO1 | TAAR1 1797/4885TYMP 4/4885HPGD 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.